Royal Stoke University Hospital

Ref: FOIA Reference 2018/19-450   **Quality, Safety and Compliance Department**
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 2nd November 2018

Tel: 01782 676474
Email FOI@uhnm.nhs.uk

Dear

I am writing in response to your email dated 26th October 2018 requesting information under the Freedom of Information Act (2000) regarding cancer treatments.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1   In the past 3 months, how many mNSCLC patients were treated with?
- **Afatinib**
- **Atezolizumab**
- **Becacizumab**
- **Ceritinib**
- **Crizotinib**
- **Erlotinib**
- **Gefitinib**
- **Nitendaninb**
- **Nivolumab**
- **Pembrolizumab**
- **Pemetrexed**
- **Ramucirumab**

A1   Please see below :(the past 3 months: July 2018 to September 2018)

Afatinib	4
Atezolizumab	7
Bevacizumab	0
Ceritinib	1
Crizotinib	1
Erlotinib	2
Gefitinib	2
Nintedanib	9
Nivolumab	3
Pembrolizumab	29
Pemetrexed	31

Ramucirumab	0

Q2 **Metastatic hepatocellular carcinoma**
In the past three months, how many patients were treated with?
- **Bevacizumab**
- **Cisplatin**
- **Doxorubicin**
- **Everolimus**
- **Lapatinib**
- **Levantinib**
- **Regorafenib**
- **Sorafenib**
- **Sunitinib**
- **TACE**
- **Other active systemic anti-cancer therapy**

A2 Please see below:(past 3 months, July 2018 to September 2018)

Bevacizumab	0
Cisplatin	0
Doxorubicin	0
Everolimus	0
Lapatinib	0
Lenvatinib	0
Regorafenib	0
Sorafenib	0
Sunitinib	0
TACE	2
Other active systemic anti-cancer therapy	Nil

Q3 **Metastatic Thyroid Cancer**
In the past three months, how many patients were treated with?
- **Axitinib**
- **Cabozantinib**
- **Levantinib**
- **Pazopanib**
- **Sorafenib**
- **Sunitinib**
- **Vandetanib**
- **Others**

A3 Please see below:(past 3 months, July 2018 to September 2018)

Axitinib	0
Cabozantinib	0
Lenvatinib	2
Pazopanib	0
Sorafenib	0
Sunitinib	0
Vandetanib	1
Others	Nil

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,

Leah Carlisle
Deputy Head of Quality, Safety & Compliance